Liaoning Chengda Biotechnology Co., Ltd. (SHA:688739)

China · Delayed Price · Currency is CNY

20.68

-0.86 (-3.99%)

At close: Aug 21, 2026

-28.57% (1Y)

Market Cap	8.50B -28.6%
Revenue (ttm)	1.31B -21.8%
Net Income	57.66M -82.7%
EPS	0.14 -82.3%
Shares Out	411.25M
PE Ratio	144.91
Forward PE	45.96
Dividend	0.10 (0.49%)
Ex-Dividend Date	Jun 3, 2026

Volume	5,305,228
Open	21.39
Previous Close	21.54
Day's Range	20.66 - 21.49
52-Week Range	18.91 - 29.63
Beta	0.42
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 25, 2026

About SHA:688739

Liaoning Chengda Biotechnology Co., Ltd., a biopharmaceutical company, engages in the research, development, production, and sale of vaccines in China and internationally. It offers inactivated Japanese encephalitis and SPEEDA-rabies vaccines. The company also develops rabies vaccine which is in new drug approval stage; influenza vaccine which is in new drug application stage; recombinant human papillomavirus 15-valent vaccine which is in Phase II clinical stage; and 13-valent pneumococcal polysaccharide conjugate, varicella, and meningococcal ... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2002

Employees 1,781

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 688739

Full Company Profile

Financial Performance

In 2025, SHA:688739's revenue was 1.39 billion, a decrease of -17.06% compared to the previous year's 1.68 billion. Earnings were 131.79 million, a decrease of -61.56%.

Financial Statements